Serum matrix metalloproteinase-3 concentration is influenced by MMP-3 - 1612 5A/6A promoter genotype and associated with myocardial infarction

Journal of Internal Medicine

Volumn 258, Issue 5, 2005, Pages 411-419

  Samnegård, Ann ^a,b   Silveira, A ^a   Lundman, P ^b   Boquist, S ^a   Odeberg, J ^a   Hulthe, J ^c   McPheat, W ^c   Tornvall, P ^a   Bergstrand, L ^b   Ericsson, C G ^b   Hamsten, A ^a   Eriksson, P ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

Coronary angiography; Matrix metalloproteinase 3; Myocardial infarction; Polymorphism; Single nucleotide

Indexed keywords

BIOLOGICAL MARKER; STROMELYSIN;

ADULT; ALLELE; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DISEASE MARKER; DISEASE SEVERITY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HEART INFARCTION; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RISK ASSESSMENT;

CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; FEMALE; GENOTYPE; HUMANS; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; MYOCARDIAL INFARCTION; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 27544438174     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2005.01561.x     Document Type: Article

References (28)

1. Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem 1996; 271: 13055-60.
2. Henney A, Wakeley P, Davies M et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci U S A 1991; 88: 8154-8.
3. Galis Z, Sukhova G, Lark M, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-503.
4. Ye S, Watts G, Mandalia S, Humphries S, Henney A. Preliminary report: Genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 1995; 73: 209-15.
5. Medley TL, Kingwell BA, Gatzka CD, Pillay P, Cole TJ. Matrix metalloproteinase-3 genotype contributes to age-related aortic stiffening through modulation of gene and protein expression. Circ Res 2003; 92: 1254-61.
6. Ghilardi G, Biondi ML, DeMonti M, Turri O, Guagnellini E, Scorza R. Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with carotid artery stenosis. Stroke 2002; 33: 2408-12.
7. Eriksson P, Deguchi H, Samnegard A et al. Human evidence that the cystatin C gene is implicated in focal progression of coronary artery disease. Arterioscler Thromb Vasc Biol 2004; 24: 551-7.
8. Austen W, Edwards J, Frye R et al. A reporting system on patients evaluated for coronary artery disease. Report of the ad hoc committee for grading of coronary artery disease, council on cardiovascular surgery. American Heart Association. Circulation 1975; 51: 5-40.
9. Carlson K. Lipoprotein fractionation. J Clin Pathol Suppl 1973; 5: 32-7.
10. Ronaghi M, Uhlén M, Nyrén P. DNA sequencing: a sequencing method based on real-time pyrophosphate. Science 1998; 281: 363-5.
11. Jones CB, Sane DC, Herrington DM. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res 2003; 59: 812-23.
12. Zucker S, Lysik R, Zarrabi M et al. Elevated plasma stromelysin levels in arthritis. J Rheumatol 1994; 21: 2329-33.
13. Masuhara K, Nakai T, Yamaguchi K, Yamasaki S, Sasaguri Y. Significant increases in serum and plasma concentrations of matrix metalloproteinases 3 and 9 in patients with rapidly destructive osteoarthritis of the hip. Arthritis Rheum 2002; 46: 2625-31.
14. Johansson N, Ahonen M, Kahari V. Matrix metalloproteinases in tumor invasion. Cell Mol Life Sci 2000; 57: 5-15.
15. Wang JC, Novetsky A, Chen C, Novetsky AD. Plasma matrix metalloproteinase and tissue inhibitor of metalloproteinase in patients with agnogenic myeloid metaplasia or idiopathic primary myelofibrosis. Br J Haematol 2002; 119: 709-12.
16. Beaudeux J-L, Giral P, Bruckert E, Bernard M, Foglietti M-J, Chapman MJ. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia. Atherosclerosis 2003; 169: 139-46.
17. Noji Y, Kajinami K, Kawashiri M et al. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med 2001; 39: 380-4.
18. Inoue T, Kato T, Takayanagi K et al. Circulating matrix metalloproteinase-1 and -3 in patients with an acute coronary syndrome. Am J Cardiol 2003; 92: 1461-4.
19. Hirashiki A, Yamada Y, Murase Y et al. Association of gene polymorphisms with coronary artery disease in low- or high-risk subjects defined by conventional risk factors. J Am Coll Cardiol 2003; 42: 1429-37.
20. Terashima M, Akita H, Kanazawa K et al. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation 1999; 99: 2717-9.
21. Beyzade S, Zhang S, Wong Y-K, Day INM, Eriksson P, Ye S. Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction. J Am Coll Cardiol 2003; 41: 2130-7.
22. Schwarz A, Haberbosch W, Tillmanns H, Gardemann A. The stromelysin-1 5A/6A promoter polymorphism is a disease marker for the extent of coronary heart disease. Dis Markers 2002; 18: 121-8.
23. Kim J, Park H, Kwon J et al. The roles of stromelysin-1 and the gelatinase B gene polymorphism in stable angina. Yonsei Med J 2002; 43: 473-81.
24. Pollanen PJ, Lehtimaki T, Ilveskoski E et al. Coronary artery calcification is related to functional polymorphism of matrix metalloproteinase 3: The Helsinki Sudden Death Study. Atherosclerosis 2002; 164: 329-35.
25. Yamada Y, Izawa H, Ichihara S et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002; 347: 1916-23.
26. Humphries S, Martin S, Cooper J, Miller G. Interaction between smoking and the stromelysin-1 (MMP3) gene 5A/6A promoter polymorphism and risk of coronary heart disease in healthy men. Ann Hum Genet 2002; 66: 343-52.
27. Gnasso A, Motti C, Irace C et al. Genetic variation in human stromelysin gene promoter and common carotid geometry in healthy male subjects. Arterioscler Thromb Vasc Biol 2000; 20: 1600-5.
28. Lee Y, Lee E, Kwon Y et al. Effect of estrogen on the expression of matrix metalloproteinase (MMP)-1, MMP-3, and MMP-13 and tissue inhibitor of metalloproternase-1 in osteoarthritis chondrocytes. Rheumatol Int 2003; 23: 282-8.